Improved Efficacy of Selective Laser Trabeculoplasty With the Addition of Rocklatan Post-treatment vs Artificial Tears Post-treatment

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Observational
SUMMARY

A randomized, single-site, parallel-group, prospective study of patients who are candidates for SLT, to study the effect of IOP change with Rocklatan vs artificial tears.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
View:

• Patients 18 years and older

• Documented diagnosis of mild to moderate primary open angle glaucoma or ocular hypertension. Diagnosis of primary open angle glaucoma must be supported by the following:

‣ 24-2 SITA faster within the last 6 months

‣ \- With a mean deviation of 0 to -12 dB, excluding patients that meet severe criteria by having defects involving fixation or in two hemispheres.

⁃ OCT RNFL and optic nerve examination within the last 6 months

• Diffuse or focal narrowing or notching of the optic disc rim, progressive narrowing of the neuroretinal rim, diffuse or localized thinning of the parapapillary RNFL, optic disc asymmetry of the two eyes consistent with loss of neural tissue, or thinning of the RNFL/GCA on examination or imaging

∙ Progressive thinning on SD-OCT of 7 microns in inferior and superior quadrants or \>4 micron loss in global RNFL thickness

∙ Deviation from this ISNT rule (inferior, superior, nasal and temporal order of RNFL thickness with the inferior RNFL quadrant being the thickness)

• Candidate for bilateral SLT

• Post-washout, post-SLT IOPs between 28-10

• Gonioscopy findings of Schafer grade III and IV

Locations
United States
Colorado
Colorado Ophthalmology Associates PC
RECRUITING
Denver
Contact Information
Primary
Cristian Mendez
cmendez@coaeyes.com
303-320-1777
Time Frame
Start Date: 2025-02-14
Estimated Completion Date: 2026-01-31
Participants
Target number of participants: 70
Treatments
Rocklatan
netarsudil and latanoprost ophthalmic solution 0.02%/0.005%
Systane Ultra
artificial tears
Sponsors
Leads: Colorado Ophthalmology Associates PC
Collaborators: Sengi

This content was sourced from clinicaltrials.gov